Madrigal Press Releases

Madrigal Pharmaceuticals

Skip to content

About Us
Our Approach
News Room
Investors

News Room

Headlines
Presentations
Media Contact

Headlines

Madrigal is pleased to announce that EASL has selected our abstract for oral presentation at the International Liver Congress™ 2020 in London, running from April 15-19.
February 28, 2020

Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
February 26, 2020

Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))
December 18, 2019

Press Release History

©2020 Madrigal Pharmaceuticals, Inc. All rights reserved.

- About Us
- Our Approach
- News Room
- Investors
- Contact Us
- Legal
- Privacy
- Cookies

Madrigal Pharmaceuticals
200 Barr Harbor Drive Suite 200 West Conshohocken, PA 19428

Madrigal Clinical Trials

Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)

Website Developed by Alan Leff Associates, Inc.